PDF(Pubmed)
Abstract：
Our aim was to perform a perfluorobutylpentane (F4H5) washout in conjunction with glaucoma drainage device (GDD) placement in patients with silicone oil (SO)-induced glaucoma. In this report we present our preliminary results concerning the effectiveness in clearing the SO and the safety of the procedure.
Eight patients who previously underwent pars plana vitrectomy with SO tamponade due to retinal detachment were selected. Removal of SO was performed on average 10 months after initial surgery. All patients developed glaucoma with evidence of SO remnants in the anterior chamber (AC) and angle. Removal of the remaining SO with F4H5 washout was performed in all cases with concomitant insertion of a GDD to treat the refractory glaucoma. Intraocular pressure (IOP), SO remnants, endothelial cell count, and need for glaucoma medications were evaluated up to 12 months after the surgical procedure.
All patients had uneventful surgery with no major complications 12 months postoperatively. A marked reduction of SO remnants in the AC and angle was observed in all cases after surgery. There was a 60.9% decrease in mean IOP 12 months postoperatively (p<0.05) and the need for glaucoma medication was lower in all patients (mean topical medicines: 4 preoperatively vs. 0.75±0.89 postoperatively; p<0.05). Endothelial cell density showed no significant change (mean 2012±129 cells/mm2 preoperatively vs. 1985±134 cells/mm2 postoperatively; p>0.05), and there were no signs of corneal edema.
F4H5 is an effective emulsifier for removing SO remnants and may be safely used in conjunction with GDD placement in order to control IOP in eyes with silicone oil-induced glaucoma.
Eight patients who previously underwent pars plana vitrectomy with SO tamponade due to retinal detachment were selected. Removal of SO was performed on average 10 months after initial surgery. All patients developed glaucoma with evidence of SO remnants in the anterior chamber (AC) and angle. Removal of the remaining SO with F4H5 washout was performed in all cases with concomitant insertion of a GDD to treat the refractory glaucoma. Intraocular pressure (IOP), SO remnants, endothelial cell count, and need for glaucoma medications were evaluated up to 12 months after the surgical procedure.
All patients had uneventful surgery with no major complications 12 months postoperatively. A marked reduction of SO remnants in the AC and angle was observed in all cases after surgery. There was a 60.9% decrease in mean IOP 12 months postoperatively (p<0.05) and the need for glaucoma medication was lower in all patients (mean topical medicines: 4 preoperatively vs. 0.75±0.89 postoperatively; p<0.05). Endothelial cell density showed no significant change (mean 2012±129 cells/mm2 preoperatively vs. 1985±134 cells/mm2 postoperatively; p>0.05), and there were no signs of corneal edema.
F4H5 is an effective emulsifier for removing SO remnants and may be safely used in conjunction with GDD placement in order to control IOP in eyes with silicone oil-induced glaucoma.
摘要：
■我们的目的是在硅油（SO）诱导的青光眼患者中，结合青光眼引流装置（GDD）放置进行全氟丁基戊烷（F4H5）冲洗。在本报告中，我们介绍了有关清除SO的有效性和程序安全性的初步结果。
■选择了8名因视网膜脱离而接受过玻璃体切割伴SO填塞的患者。初次手术后平均10个月进行SO去除。所有患者均出现青光眼，前房（AC）和房角均有SO残留物。在所有情况下，都使用F4H5冲洗去除剩余的SO，并同时插入GDD以治疗难治性青光眼。眼内压(IOP),所以残余物，内皮细胞计数,在手术后12个月内评估青光眼药物的需要。
■所有患者手术顺利，术后12个月无重大并发症。在手术后的所有情况下，都观察到AC和角度中SO残留物的显着减少。术后12个月的平均IOP下降了60.9％（p<0.05），所有患者对青光眼药物的需求均较低（平均局部用药：术前4术后0.75±0.89；p<0.05）。内皮细胞密度无明显变化（术前平均2012±129个细胞/mm2与术后1985±134细胞/mm2；p>0.05)，并且没有角膜水肿的迹象。
■F4H5是去除SO残留物的有效乳化剂，可以安全地与GDD放置结合使用，以控制硅油诱导的青光眼眼睛的IOP。
■选择了8名因视网膜脱离而接受过玻璃体切割伴SO填塞的患者。初次手术后平均10个月进行SO去除。所有患者均出现青光眼，前房（AC）和房角均有SO残留物。在所有情况下，都使用F4H5冲洗去除剩余的SO，并同时插入GDD以治疗难治性青光眼。眼内压(IOP),所以残余物，内皮细胞计数,在手术后12个月内评估青光眼药物的需要。
■所有患者手术顺利，术后12个月无重大并发症。在手术后的所有情况下，都观察到AC和角度中SO残留物的显着减少。术后12个月的平均IOP下降了60.9％（p<0.05），所有患者对青光眼药物的需求均较低（平均局部用药：术前4术后0.75±0.89；p<0.05）。内皮细胞密度无明显变化（术前平均2012±129个细胞/mm2与术后1985±134细胞/mm2；p>0.05)，并且没有角膜水肿的迹象。
■F4H5是去除SO残留物的有效乳化剂，可以安全地与GDD放置结合使用，以控制硅油诱导的青光眼眼睛的IOP。
